Current Editions
China is redefining time-to-clinic, and it could be transformational: a Perspective
A new standard for swift entry
Editor's Commentary
Product Development
China’s Innovation Moment: Takeaways from the 12th China Healthcare Summit
On BioCentury’s latest podcast: Paradigm-shifting speed of development, landmark deals, homegrown talent and a surging Hong Kong market
Data Byte
At least four PDUFA dates on FDA’s November docket
Decisions expected for Arrowhead siRNA, Kura AML small molecule
Finance
Hong Kong queue swells with IPO, dual listing candidates: Finance Report
BrightGene, NovaBridge, Alebund, Ribo and Lupeng all seek HKSE offerings; MapLight gives back its gains; and more
BioCentury ISSN 1097-7201